Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Kiniksa Pharmaceuticals International, plc before investing.

In this article, we go over a few key elements for understanding Kiniksa Pharmaceuticals International, plc’s stock price such as:

• Kiniksa Pharmaceuticals International, plc’s current stock price and volume
• Why Kiniksa Pharmaceuticals International, plc’s stock price changed recently
• Upgrades and downgrades for KNSA from analysts
• KNSA’s stock price momentum as measured by its relative strength

About Kiniksa Pharmaceuticals International, plc (KNSA)

Before we jump into Kiniksa Pharmaceuticals International, plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Want to learn more about Kiniksa Pharmaceuticals International, plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Kiniksa Pharmaceuticals International, plc.

Kiniksa Pharmaceuticals International, plc’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Kiniksa Pharmaceuticals International, plc’s stock price was $74.340.

Kiniksa Pharmaceuticals International, plc is down 4.94% from its previous closing price of $78.200.

During the last market session, Kiniksa Pharmaceuticals International, plc’s stock traded between $73.650 and $78.040. Currently, there are approximately 77.58 million shares outstanding for Kiniksa Pharmaceuticals International, plc.

Kiniksa Pharmaceuticals International, plc’s price-earnings (P/E) ratio is currently at 79.0, which is high compared to the Biotechnology industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Kiniksa Pharmaceuticals International, plc Stock Price History

Kiniksa Pharmaceuticals International, plc’s (KNSA) price is currently up 16.25% so far this month.

During the month of July, Kiniksa Pharmaceuticals International, plc’s stock price has reached a high of $82.940 and a low of $60.065.

Over the last year, Kiniksa Pharmaceuticals International, plc has hit prices as high as $82.940 and as low as $29.900. Year to date, Kiniksa Pharmaceuticals International, plc’s stock is up 80.22%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Kiniksa Pharmaceuticals International, plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Kiniksa Pharmaceuticals International, plc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Kiniksa Pharmaceuticals International, plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Kiniksa Pharmaceuticals International, plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Kiniksa Pharmaceuticals International, plc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Kiniksa Pharmaceuticals International, plc (KNSA) by visiting AAII Stock Evaluator.

Relative Price Strength of Kiniksa Pharmaceuticals International, plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Kiniksa Pharmaceuticals International, plc has a weighted four-quarter relative price strength of 26.29%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Kiniksa Pharmaceuticals International, plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Kiniksa Pharmaceuticals International, plc Stock Price: Bottom Line

As of July 31, 2026, Kiniksa Pharmaceuticals International, plc’s stock price is $74.340, which is down 4.94% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Kiniksa Pharmaceuticals International, plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.